Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy Alone Repatha is Now the First and Only ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) on Monday released topline data from RSVHR Phase 2b study of zelicapavir in outpatient adults with acute respiratory syncytial virus (RSV) infection who are ...

MoonLake Immunotherapeutics will still file for approval of the IL-17 with the FDA. Image credit: Piotr Swat / Shutterstock.com. MoonLake Immunotherapeutics’s stock has crashed after its hidradenitis ...

The Alzheimer’s disease market is expected to grow at a high compound annual growth rate (CAGR) of 21.8% from $2.4bn in 2023 to $17bn by 2033. Image credit: Antonio Marca / Shutterstock.com Eli Lilly ...

Swiss biotech MoonLake Immunotherapeutics (Nasdaq: MLTX) has released top-line data from two Phase III trials of its inflammatory disease candidate sonelokimab in hidradenitis suppurativa, with mixed ...

VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (HS) and the first Phase 3 program ...

In the combined Phase 3 VELA program, all endpoints reached statistical significance with p-values below 0.001, including lesion counts and patient reported outcomes (PROs), as per Table 2.

This score calculates overall vulnerability severity from 0 to 10 and is based on the Common Vulnerability Scoring System (CVSS). Attack vector: More severe the more the remote (logically and ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Between Sept 27, 2021, and ...

Paltusotine is the first once-daily oral therapy approved for acromegaly, offering a non-invasive alternative to injections. PATHFNDR-1 and PATHFNDR-2 trials showed significant efficacy in IGF-1 ...